Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Theraclion S.A. (ALTHE.PA)
EUR0.67
+0.01 (+1.36%)
FR PAR Healthcare Medical - Devices
Address
102 Rue Etienne Dolet 92240
Malakoff, FR
Malakoff, FR
CEO
Martin Deterre
Website
theraclion.com
IPO
2014-04-25
ISIN FR0010120402
Also trades on
Euronext Paris · ALTHE.PA (EUR)
Other OTC · TCLIF (USD)
Description
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR0.67
+0.01 (+1.36%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
198.2K
Beta
0.37
Float Shares
33.39M
Free Float %
70.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.33% | +42.33% | +45.00% | +11.90% | +7.08% | +15.61% | +146.81% | +14.85% | -56.50% | -88.60% | -94.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.67
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.04
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+42.9% ★ Q4'25: -58.2% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+18.5% Q4'25: -106.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-479.9% Q4'25: -1,072.2% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-537.4% Q4'25: -629.0% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%— Q4'25: +904.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+26.2% Q4'25: +27.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.80× Q4'25: -0.57× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.60M
est: 1.83M (-12.8%)
|
1.98M
est: 1.80M (+9.7%)
|
2.82M
est: 2.43M (+16.3%)
|
1.94M
est: 1.90M (+2.1%)
|
2.78M
est: 2.78M (+0.0%)
|
744.0K
est: 744.0K (+0.0%)
|
1.48M
est: 1.48M (+0.0%)
|
1.24M
est: 1.24M (+0.0%)
|
1.82M
est: 3.83M (-52.4%)
|
830.0K
est: 11.86M (-93.0%)
|
1.19M
est: 1.19M (+0.0%)
|
| EBITDA |
-6.73M
est: -1.83M (-267.4%)
|
-7.17M
est: -1.80M (-298.3%)
|
-6.74M
est: -9.20M (+26.8%)
|
-6.62M
est: -1.90M (-248.6%)
|
-4.48M
est: -9.19M (+51.3%)
|
-4.15M
est: -744.0K (-457.7%)
|
-4.40M
est: -9.75M (+54.8%)
|
-5.74M
est: -17.87M (+67.9%)
|
-4.49M
est: -34.59M (+87.0%)
|
-6.96M
est: -65.77M (+89.4%)
|
-6.37M
est: -1.19M (-437.4%)
|
| EBIT |
-7.08M
est: -1.83M (-286.4%)
|
-7.51M
est: -1.80M (-317.1%)
|
-7.14M
est: -9.27M (+23.0%)
|
-7.06M
est: -1.90M (-271.8%)
|
-4.80M
est: -9.20M (+47.8%)
|
-4.29M
est: -744.0K (-476.4%)
|
-4.53M
est: -9.68M (+53.1%)
|
-5.92M
est: -17.75M (+66.6%)
|
-4.69M
est: -34.34M (+86.3%)
|
-6.74M
est: -65.29M (+89.7%)
|
-6.37M
est: -1.19M (-437.4%)
|
| Net Income |
-6.41M
est: -47.30M (+86.4%)
|
-6.54M
est: -70.52M (+90.7%)
|
-6.22M
est: -8.42M (+26.1%)
|
-6.14M
est: -31.34M (+80.4%)
|
-3.79M
est: -8.01M (+52.7%)
|
-3.91M
est: -9.50M (+58.9%)
|
-3.76M
est: -7.58M (+50.4%)
|
-4.96M
est: -13.90M (+64.3%)
|
-3.68M
est: -26.91M (+86.3%)
|
-5.76M
est: -22.85M (+74.8%)
|
-5.69M
|
| SGA |
3.52M
est: 720.0K (+389.5%)
|
4.30M
est: 707.8K (+506.9%)
|
2.89M
est: 955.1K (+202.4%)
|
2.56M
est: 747.1K (+242.4%)
|
590.0K
est: 1.09M (-46.1%)
|
479.0K
est: 292.5K (+63.7%)
|
224.0K
est: 582.3K (-61.5%)
|
5.8K
est: 485.6K (-98.8%)
|
—
est: 1.50M (-100.0%)
|
968.0K
est: 5.73M (-83.1%)
|
1.30M
est: 573.2K (+126.4%)
|
| EPS |
-1.58
est: -1.03 (-54.0%)
|
-1.01
est: -1.53 (+34.0%)
|
-0.83
est: -0.46 (-80.4%)
|
-0.73
est: -0.68 (-7.4%)
|
-0.25
est: -0.45 (+44.7%)
|
-0.24
est: -0.21 (-16.4%)
|
-0.16
est: -0.19 (+17.8%)
|
-0.17
est: -0.20 (+14.3%)
|
-0.08
est: -0.04 (-111.6%)
|
-0.12
est: 0.09 (-228.0%)
|
-0.10
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.83M
OE per share TTM
-0.15
Owner's Yield
-16.87%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-2.3K
Shares Outstanding
47.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Martin Deterre | GM & Chief Executive Officer | 222.3K | male |
| Yann Duchesne | Executive Chairman | 162.0K | male |
| Julie Veisseire | Administrative and Financial Director & CFO | — | — |
| Jérémie Anquez | Vice President Research & Chief Scientific Officer | — | — |
| Gaylord Tallec | Vice President of Operations | — | male |
| Michel Nuta | Vice President of Veins & Chief Medical Officer | — | male |
| Thibault Le Normand | Director of Sales, Marketing & Applications | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALTHE.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
